News

The study results showed the ‘CEL-2000-DepoVax’ combination considerably lessened the symptoms and slowed the progression of RA in the animal model with a single dose. The two companies

Endo said that, the new formulation of long-acting Oxymorphone designed to be crush-resistant, is a semi-synthetic opioid analgesic intended for the treatment of moderate to severe chronic pain

The Sanford Project aims to cure T1D through the development of beta cell regeneration therapies (the cells which produce insulin in the pancreas). Under the collaboration, DiaMedica is

Boehringer said that the new findings fully support the convincing results from the RE-LY trial and show that AF patients with previous stroke or transient ischemic attack (TIA)

Santabarbara joins Infinity following five years with PharmaMar, where he most recently led the development and approval of Yondelis (trabectedin). Prior to PharmaMar, he served as vice president

Williams joins Aqua following an executive director position at Watson Pharmaceuticals, where he was responsible for brand and biologics business development since 2004. In that role, Williams developed

Hamilton will be responsible for guiding the company’s clinical programs, including the PICASSO 3 trial, an international, randomised, double-blinded, placebo-controlled trial of palifosfamide and doxorubicin in patients with

As per the terms of this collaboration, Kollmann is expected to use Advaxis proprietary Listeria vaccine vectors for the development of novel infectious disease applications, and employ a

Antisoma is a London Stock Exchange-listed biopharmaceutical company that develops novel products for the treatment of cancer. The company has operations in London, UK and Cambridge, MA. Antisoma,